

# Adis Publishing Services

Jan Seal-Roberts

Director of Publishing Services

# First of all - what's all this about Wolters Kluwer?

---

- Wolters Kluwer acquired Adis in 2004
- WK is HQ'ed in NL, but many key personnel based in US
- Truly GLOBAL presence
- Key divisions: Tax + Accounting, Legal & Financial Pubs + Services and Health
- Today Wolters Kluwer is a collection of several very well-known 'brands', including
  - Adis (Australasian Drug Information Service)
  - LWW (Lippincott Williams & Wilkins)
  - Ovid
  - Also several other cos in US: Healthcare Analytics, IFI Patent Intelligence, Medi-Span, Facts & Comparisons, Source
- Wolters Kluwer is BIG!



# What are our key values?

---

- **Customer focus**  
We develop products, services, and solutions with our customers' needs in mind. We listen to our customers and treat them with professionalism, honesty, and respect.
- **Innovation**  
We create bold and forward-looking solutions that combine the latest technologies with our unmatched subject matter expertise and deep knowledge of our customers.
- **Accountability**  
We take full responsibility for our actions and performance, and for meeting customers' needs and shareholders' expectations. We keep our promises.
- **Integrity**  
We are direct, honest, transparent, and fair in our business dealings. We encourage diversity and respect the ideas and points of view of others.
- **Value creation**  
We create value for our customers, employees, and shareholders. We strive for excellence in everything we do.
- **Teamwork**  
We work together with our customers, partners, and each other to meet our business goals.

# Introduction to Adis

---

- Adis as a publishing brand has evolved over 40 years from an editorial base in Auckland, New Zealand
- Currently **21 journals and newsletters** covering all areas of pharmacology and pharmacotherapy
- We focus on good customer service for authors, including quick response times and cascading peer-review
- Our most used phrases? **‘Good Publication Practice’ ‘Rapid’**
- What our customers most often say? **‘Wow! That was quick!’ ‘Excellent!’**



Adis

a Wolters Kluwer business

# Subject Area Strengths (1)

- Generalist (3 tiers) + Primary Care



	Readership	Impact Factor	Timelines	Rejection Rate	Medline Indexed	Published	Geographic distribution
<i>Clinical Drug Investigation</i>	62,688	1.414	S:A 4-6 wks A:P 2-4 wks	47%	Yes	Monthly	Americas 40%; Europe 40%; Asia 20%; ROW 0%
<i>Drugs</i>	453,238	4.732	S:A 4-12 wks A:P 8-16 wks	68%	Yes	Three-Weekly	Americas 38%; Europe 40%; Asia 20%; ROW 2%
<i>Drugs in R&amp;D</i>	19,649	1.354	S:A 1-2 wks A:P 4-12 wks	N/A	Yes	Quarterly	Americas 59%; Europe 19%; Asia 20%; ROW 3%

# Subject Area Strengths (2)


- Health Outcomes



	Readership	Impact Factor	Timelines	Rejection Rate	Medline Indexed	Published	Geographic distribution
<i>Applied Health Economics &amp; Health Policy</i>	19,932	N/A	S:A 4-12 wks A:P 8-24 wks	60%	Yes	Bi-Monthly	Americas 42%; Europe 23%; Asia 33%; ROW 2%
<i>PharmacoEconomics</i>	111,139	2.612	S:A 4-8 wks A:P 8-16 wks	60%	Yes	Monthly	Americas 46%; Europe 39%; Asia 13%; ROW 2%
<i>The Patient: Patient-Centered Outcomes</i>	7,683	Due 2011	S:A 4-8 wks A:P 4-12 wks	N/A	No	Quarterly	Americas 51%; Europe 15%; Asia 34%; ROW 0%

# Subject Area Strengths (3)


- Special Patient Populations



	Readership	Impact Factor	Timelines	Rejection Rate	Medline Indexed	Published	Geographic distribution
<i>Drugs &amp; Aging</i>	139,827	2.209	S:A 4-12 wks A:P 8-16 wks	32%	Yes	Monthly	Americas 49%; Europe 33%; Asia 18%; ROW 0%
<i>Pediatric Drugs</i>	75,787	Due 2013	S:A 4-12 wks A:P 4-8 wks	33%	Yes	Bi-Monthly	Americas 49%; Europe 25%; Asia 23%; ROW 1%

# Subject Area Strengths (4)

- Therapy Areas: Cardiovascular, CNS and Dermatology




	Readership	Impact Factor	Timelines	Rejection Rate	Medline Indexed	Published	Geographic distribution
American Journal of Cardiovascular Drugs	58,948	1.964	S:A 4-12 wks A:P 4-8 wks	22%	Yes	Bi-Monthly	Americas 65%; Europe 21%; Asia 14%; ROW 0%
American Journal of Clinical Dermatology	115,207	1.820	S:A 4-12 wks A:P 8-16 wks	77%	Yes	Bi-Monthly	Americas 46%; Europe 29%; Asia 23%; ROW 2%
CNS Drugs	186,158	3.879	S:A 4-12 wks A:P 8-16 wks	44%	Yes	Monthly	Americas 47%; Europe 36%; Asia 16%; ROW 1%



# Subject Area Strengths (5)

- Specific Disciplines



	Readership	Impact Factor	Timelines	Rejection Rate	Medline Indexed	Published	Geographic distribution
<i>BioDrugs</i>	76,473	3.506	S:A 4-12 wks A:P 4-8 wks	60%	Yes	Bi-Monthly	Americas 50%; Europe 25%; Asia 25%; ROW 0%
<i>Clinical Pharmacokinetics</i>	158,691	4.560	S:A 4-12 wks A:P 8-16 wks	55%	Yes	Monthly	Americas 40%; Europe 35%; Asia 24%; ROW 1%
<i>Drug Safety</i>	173,138	3.522	S:A 4-12 wks A:P 8-16 wks	65%	Yes	Monthly	Americas 39%; Europe 41%; Asia 19%; ROW 0%



## Two key features that Adis offers

---

- Adis Drug Profiles and Drug Evaluations
- Adis Rapid Publication Service

# Adis Drug Evaluations and Drug Profiles

## ADIS DRUG EVALUATION

Drugs 2010; 70 (17): 2290-2313  
0012-6667/10/0017-2290/\$55.55/0

© 2010 Adis Data Information BV. All rights reserved.

## Olanzapine Long-Acting Injection

### A Review of its Use in the Treatment of Schizophrenia

James E. Frampton

Adis, a Wolters Kluwer Business, Auckland, New Zealand

#### Various sections of the manuscript reviewed by:

P. Mohr, Department of Psychiatry 3rd Faculty of Medicine, Charles University, Prague, Czech Republic; L. Samalin, Centre Hospitalier Universitaire, Clermont-Ferrand, France; D. Taylor, Pharmacy Department, Maudsley Hospital, London, England; M. Taylor, NHS Lothian Psychiatry, Edinburgh, Scotland.

#### Data Selection

**Sources:** Medical literature published in any language since 1980 on 'olanzapine', identified using MEDLINE and EMBASE, supplemented by AdisBase (a proprietary database). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug.

**Search strategy:** MEDLINE, EMBASE and AdisBase search terms were ('olanzapine') and ('schizophrenia') and ('long-acting') and ('intramuscular' or 'injection'). Searches were last updated 8 November 2010.

**Selection:** Studies in patients with schizophrenia who received olanzapine long-acting injection. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included.

**Index terms:** Olanzapine long-acting injection, intramuscular depot preparation, schizophrenia, pharmacodynamics, pharmacokinetics, therapeutic use, tolerability.

#### Contents

Abstract	2290
1. Introduction	2290
2. Pharmacological Properties	2291
2.1 Pharmacodynamic Properties	2291
2.2 Pharmacokinetic Properties	2292
2.2.1 Absorption and Distribution	2292
2.2.2 Metabolism and Elimination	2293
2.2.3 Special Patient Populations	2293
2.2.4 Drug-Drug Interactions	2294
3. Therapeutic Efficacy	2294
3.1 Short-Term Treatment	2295
3.2 Maintenance Treatment	2296
3.2.1 Open-Label Studies	2298
4. Tolerability	2300
4.1 General Profile	2300
4.2 Injection-Site-Related Adverse Events	2301
4.2.1 Post-Injection Syndrome	2301
4.3 Metabolic and Laboratory Adverse Events	2302
4.3.1 Bodyweight	2302
4.3.2 Plasma Glucose and Lipid Levels	2303
4.3.3 Liver Function Tests and Prolactin Levels	2304
4.4 Vital Signs	2304
4.5 Extrapyramidal Symptoms	2304

- Single-agent focus highlights unique benefits of a drug.
- Adis author ensures expert writing and independence.
- Exhaustive peer review by up to 10 key opinion leaders ensures objectivity and credibility.
- Comprehensive, systematic approach.
- Clear and structured presentation offers readers easy access to the data at several levels.
- Focus on clinically relevant aspects of the drug helps define its place in therapy - a useful tool for practitioners.




Adis  
a Wolters Kluwer business

# Rapid Publication of Original Research

## Adis Rapid Publishing Process

We recommend discussing the content of your original manuscript with the appropriate journal editor prior to submission. They are very willing to give advice about appropriate target journals within the Adis portfolio and to help you to prepare your paper in the correct way.

Following submission, dedicated managing editors will work closely with you to create a schedule based on the timelines opposite. They will liaise with you throughout the process, ensuring that the project remains on track to meet the deadlines agreed.



© 2009 Wolters Kluwer Health



## Take home messages from today?

---

- We may seem quite small - but are actually part of something big
- We have a number of high-impact journals that might be just right for your pub needs
- We are hot on editorial independence/integrity (we endorse ICMJE guidelines and COPE code of conduct for editors)
- We pride ourselves on good customer service - but editorial integrity always comes first!
- **Drugs in R&D** as rapid open-access option
- **Drugs** as a high-impact rapid pub option for pivotal head-to-head studies
- We offer cascading peer review service - thus big time-saving benefits
- We can offer article usage stat reports (full text views and ranking of views within that journal) from Adis Online post-publication if required
- **Please contact me to discuss how we can help you!**

# Thank You!

---



Jan Seal-Roberts

[jan.roberts@wolterskluwer.com](mailto:jan.roberts@wolterskluwer.com)

